Safety and Efficacy Study of a New Chemotherapy Agent to Treat Non-small-cell Lung Cancer
Phase II Study to Investigate the Efficacy and Safety of ZK 219477 as Second Line Therapy in Patients With Stage IIIB or Stage IV Non Small Cell Lung Cancer (NSCLC)
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Berlin, Germany, 12200
-
Berlin, Germany, 14165
-
Bremen, Germany, 29325
-
Ebensfeld, Germany, 96250
-
Hamburg, Germany, 21075
-
-
Baden-Württemberg
-
Löwenstein, Baden-Württemberg, Germany, 74245
-
-
Bayern
-
Augsburg, Bayern, Germany, 86156
-
Gauting, Bayern, Germany, 82131
-
Nürnberg, Bayern, Germany, 90419
-
-
Hessen
-
Frankfurt, Hessen, Germany, 60590
-
Frankfurt, Hessen, Germany, 65929
-
-
Mecklenburg-Vorpommern
-
Greifswald, Mecklenburg-Vorpommern, Germany, 17475
-
Stralsund, Mecklenburg-Vorpommern, Germany, 17475
-
-
Sachsen
-
Leipzig, Sachsen, Germany, 04103
-
-
Sachsen-Anhalt
-
Halle, Sachsen-Anhalt, Germany, 06120
-
Magdeburg, Sachsen-Anhalt, Germany, 39130
-
-
Schleswig-Holstein
-
Großhansdorf, Schleswig-Holstein, Germany, 22927
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Non-small-cell lung cancer
- Only one previous chemotherapy with a platinum-containing drug
- Use of highly effective birth control methods in females of child-bearing potential
Exclusion Criteria:
- No more than 1 previous chemotherapy for advanced disease
- Previous participation in another trial within the last 4 weeks
- Breast feeding
- Active infections
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Arm 1
|
16 mg/m2, 3-hour infusion, every 3 weeks
22 mg/m2, 30-min infusion, every 3 weeks
22 mg/m2, 3-hour infusion, every 3 weeks
|
|
Experimental: Arm 2
|
16 mg/m2, 3-hour infusion, every 3 weeks
22 mg/m2, 30-min infusion, every 3 weeks
22 mg/m2, 3-hour infusion, every 3 weeks
|
|
Experimental: Arm 3
|
16 mg/m2, 3-hour infusion, every 3 weeks
22 mg/m2, 30-min infusion, every 3 weeks
22 mg/m2, 3-hour infusion, every 3 weeks
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
The primary efficacy variable is defined as Proportion of patients with either CR or PR as 'best overall response'. Tumor assessment is performed according to RECIST criteria.
Time Frame: Tumor evaluation (MRI or scan) every 2 cycles until disease progression.
|
Tumor evaluation (MRI or scan) every 2 cycles until disease progression.
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Secondary objectives : investigate the safety and tolerability of ZK 219477
Time Frame: Continuously
|
Continuously
|
Collaborators and Investigators
Sponsor
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Respiratory Tract Diseases
- Neoplasms
- Lung Diseases
- Neoplasms by Site
- Respiratory Tract Neoplasms
- Thoracic Neoplasms
- Carcinoma, Bronchogenic
- Bronchial Neoplasms
- Lung Neoplasms
- Carcinoma, Non-Small-Cell Lung
- Molecular Mechanisms of Pharmacological Action
- Antineoplastic Agents
- Tubulin Modulators
- Antimitotic Agents
- Mitosis Modulators
- Epothilones
- Sagopilone
Other Study ID Numbers
Other Study ID Numbers
- 91374
- 2005-000586-19 (EudraCT Number)
- 307971 (Other Identifier: Company Internal ID)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.